SCHEMBL692156

SCHEMBL692156

Nc1cc[nH]c(=O)c1-c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.56
AURKA O14965 2/20 0.47
AURKB Q96GD4 2/20 0.47
INCENP Q9NQS7 2/20 0.47
THRB P10828 1/20 0.47
CASP1 P29466 1/20 0.47
TTK P33981 1/20 0.47
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
PARP1 P09874 3/20 0.44
RECQL P46063 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
XDH P47989 1/20 0.43
JAK2 O60674 1/20 0.43
RPS6KA3 P51812 1/20 0.43
MELK Q14680 1/20 0.43
STK24 Q9Y6E0 1/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3976914 0.78 MAPT (0.63) MAPTAURKBALDH1A1PARP1JAK2
SCHEMBL25434885 0.73 AURKA (0.44) MAPTAURKAAURKBINCENPTHRB
SCHEMBL27739470 0.72 MAPT (1.00) MAPTAURKAAURKBINCENPTHRB
SCHEMBL8108278 0.72 MAPT (0.47) MAPTALDH1A1HPGDHSD17B10PARP1
SCHEMBL10760551 0.72 PIM1 (0.46) MAPTALDH1A1HPGDHSD17B10PARP1
SCHEMBL6140775 0.72 MAPT (0.43) MAPTALDH1A1HPGDHSD17B10PARP1
SCHEMBL7084711 0.72 MAPT (0.45) MAPTAURKAAURKBINCENPTHRB
SCHEMBL28988834 0.71 ALDH1A1 (0.50) MAPTALDH1A1PARP1TDP1LMNA
SCHEMBL25014 0.70 HSD17B10 (0.50) MAPTTHRBCASP1ALDH1A1HPGD
SCHEMBL29546125 0.70 HSD17B10 (0.50) MAPTTHRBCASP1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120201804-A1 TISSUE KALLIKREIN FOR THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER SANOMUNE, INC. (CA) 2012-08-09 US disclosed
EP-2421553-A1 TISSUE KALLIKREIN FOR THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER Sanomune Inc. (CA) 2012-02-29 EP disclosed
WO-2010121358-A1 TISSUE KALLIKREIN FOR THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER SANOMUNE INC. (CA) 2010-10-28 WO disclosed
US-20030216257-A1 1-aryl-4-alkyl halide-2(1h)-pyridones and their use as herbicides BASF AKTIENGESELLSCHAFT (DE) 2003-11-20 US disclosed
EP-0015773-B1 N-(6-((ACYLAMINOACYLAMINO OR AMINOACYLAMINO)PHENYL) 1,2-DIHYDRO-2-OXONICOTINYL)PENICILLIN COMPOUNDS, PROCESSES FOR THEIR PRODUCTION AND COMPOSITIONS CONTAINING THEM WARNER-LAMBERT COMPANY (US) 1983-07-20 EP disclosed
US-4278681-A N-/6-//ACYLAMINOACYLAMINO OR AMINOACYLAMINO/PHENYL/-1,2-DIHYDRO-2-OXONICOTINYL/PENICILLINS WARNER-LAMBERT CO. (US) 1981-07-14 US disclosed
EP-0015773-A2 N-(6-((acylaminoacylamino or aminoacylamino)phenyl) 1,2-dihydro-2-oxonicotinyl)penicillin compounds, processes for their production and compositions containing them WARNER-LAMBERT COMPANY (US) 1980-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216257-A1 1-aryl-4-alkyl halide-2(1h)-pyridones and their use as herbicides CYP1B1, DDT, CYP1A1 MAPT 4036/4885AURKA 1587/4885AURKB 2919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.